CN105142671B - 卡巴他赛和磺基丁基醚β-环糊精的组合物 - Google Patents

卡巴他赛和磺基丁基醚β-环糊精的组合物 Download PDF

Info

Publication number
CN105142671B
CN105142671B CN201380073396.6A CN201380073396A CN105142671B CN 105142671 B CN105142671 B CN 105142671B CN 201380073396 A CN201380073396 A CN 201380073396A CN 105142671 B CN105142671 B CN 105142671B
Authority
CN
China
Prior art keywords
cabazitaxel
composition
solution
cyclodextrin
sbecd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380073396.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105142671A (zh
Inventor
瓦莱丽·阿拉霍夫
格热戈什·皮埃特斯基
基肖尔·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Softto Kimmel Pharmaceutical Co
Original Assignee
Softto Kimmel Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Softto Kimmel Pharmaceutical Co filed Critical Softto Kimmel Pharmaceutical Co
Publication of CN105142671A publication Critical patent/CN105142671A/zh
Application granted granted Critical
Publication of CN105142671B publication Critical patent/CN105142671B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380073396.6A 2012-12-24 2013-12-23 卡巴他赛和磺基丁基醚β-环糊精的组合物 Active CN105142671B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261848172P 2012-12-24 2012-12-24
US61/848,172 2012-12-24
PCT/IB2013/003255 WO2014122498A2 (en) 2012-12-24 2013-12-23 Cabazitaxel composition

Publications (2)

Publication Number Publication Date
CN105142671A CN105142671A (zh) 2015-12-09
CN105142671B true CN105142671B (zh) 2018-09-14

Family

ID=51300216

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380073396.6A Active CN105142671B (zh) 2012-12-24 2013-12-23 卡巴他赛和磺基丁基醚β-环糊精的组合物

Country Status (16)

Country Link
US (1) US9919053B2 (enExample)
EP (1) EP2934593B1 (enExample)
JP (1) JP6498610B2 (enExample)
KR (1) KR102161866B1 (enExample)
CN (1) CN105142671B (enExample)
AU (1) AU2013377404B2 (enExample)
BR (1) BR112015015202B8 (enExample)
CA (1) CA2900508C (enExample)
DK (1) DK2934593T3 (enExample)
ES (1) ES2771423T3 (enExample)
HU (1) HUE048505T2 (enExample)
MX (1) MX371067B (enExample)
PL (1) PL2934593T3 (enExample)
PT (1) PT2934593T (enExample)
RU (1) RU2678772C2 (enExample)
WO (1) WO2014122498A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109731A1 (en) * 2016-12-16 2018-06-21 Orbicular Pharmaceutical Technologies Private Limited Pharmaceutical compositions of taxane and its derivatives
CN113559277B (zh) * 2018-01-11 2023-11-17 比卡生物科技(广州)有限公司 一种注射用卡巴他赛组合物及其制备方法
JP7274785B2 (ja) * 2018-07-25 2023-05-17 ビカ バイオテクノロジー (グアンジョウ) カンパニー リミテッド 注射用ドセタキセル組成物およびそのための調製法
KR20230079035A (ko) * 2020-09-14 2023-06-05 주하이 베이하이 바이오테크 컴퍼니 리미티드 카바지탁셀의 제형

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041625A1 (en) * 2006-09-12 2010-02-18 Nanjing Huge-Ring Medicine Technology Development Co., Ltd. Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof
US20100048685A1 (en) * 2006-09-12 2010-02-25 Yong Ren Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1443969A2 (en) * 2001-10-18 2004-08-11 Decode Genetics EHF Non-inclusion cyclodextrin complexes
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
AU2004280158B2 (en) * 2003-07-18 2011-02-17 Baxter International, Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
CA2543443A1 (en) * 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
WO2013024495A1 (en) 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041625A1 (en) * 2006-09-12 2010-02-18 Nanjing Huge-Ring Medicine Technology Development Co., Ltd. Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof
US20100048685A1 (en) * 2006-09-12 2010-02-25 Yong Ren Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery

Also Published As

Publication number Publication date
AU2013377404A2 (en) 2015-08-27
BR112015015202A2 (pt) 2017-07-11
RU2678772C2 (ru) 2019-02-01
PT2934593T (pt) 2020-03-09
MX371067B (es) 2020-01-15
BR112015015202B8 (pt) 2022-02-15
ES2771423T3 (es) 2020-07-06
HUE048505T2 (hu) 2020-07-28
BR112015015202B1 (pt) 2021-12-21
DK2934593T3 (da) 2020-02-17
CA2900508C (en) 2021-04-13
US9919053B2 (en) 2018-03-20
AU2013377404B2 (en) 2018-08-23
AU2013377404A1 (en) 2015-07-30
JP2016508138A (ja) 2016-03-17
WO2014122498A2 (en) 2014-08-14
EP2934593A4 (en) 2016-08-10
KR102161866B1 (ko) 2020-10-05
EP2934593A2 (en) 2015-10-28
RU2015130495A (ru) 2017-01-27
CA2900508A1 (en) 2014-08-14
WO2014122498A3 (en) 2014-12-04
KR20150127035A (ko) 2015-11-16
EP2934593B1 (en) 2020-02-05
PL2934593T3 (pl) 2020-05-18
JP6498610B2 (ja) 2019-04-10
MX2015008225A (es) 2016-07-20
US20150328321A1 (en) 2015-11-19
CN105142671A (zh) 2015-12-09

Similar Documents

Publication Publication Date Title
CN101330912B (zh) 一种多西他赛的药用组合物、制备方法及用途
CN107149592B (zh) 具有淋巴靶向功能的生物自组装纳米晶注射剂及制备方法
CN103054794A (zh) 难溶性药物凝胶组合物及其制备方法
CN107303272A (zh) 一种提高难溶性药物口服吸收的纳晶组合物
CN109771663B (zh) 一种酸响应性抗癌纳米药物的制备及应用
CN113271923A (zh) 呋塞米的药物组合物及其用途
CN105142671B (zh) 卡巴他赛和磺基丁基醚β-环糊精的组合物
CN111491632A (zh) 癌症治疗药
CN102232933A (zh) 具有肿瘤靶向性的白蛋白纳米冻干粉针制剂及其制备方法
CN106913882A (zh) 一种聚乙二醇‑藤黄酸脂质体和制备方法及其在治疗恶性肿瘤中的应用
CN105997942A (zh) 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
CN101411690B (zh) 2-甲氧基雌二醇脂质体冻干粉针剂及其制备方法
CN111465389B (zh) 多西他赛共缀物的药物组合物及制备方法
WO2017107894A1 (zh) 药物包合物,其制剂和制备方法
CN104511020A (zh) 一种紫杉醇的药物组合物
CN111107837A (zh) 包含西普尼莫德的肠胃外制剂
CN104511022A (zh) 一种紫杉醇的药物组合物
CN102526038A (zh) 替莫唑胺的脑靶向药物组合物及其应用
CN114903872B (zh) 共递雷公藤红素和Bcl-2-功能转换肽的树状大分子自组装体及制备方法与应用
Patil et al. Advances in Capsaicin-Based Nanocarriers: Bridging Mechanistic Insights with Therapeutic Potential and Clinical Outcomes
WO2013149538A1 (zh) 药用组合物
CA3117511C (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
CN112168785B (zh) 熊果酸脂质体制剂及其制备方法和用途
JP7267640B2 (ja) 希釈安定性に優れたテニポシド注射用溶液及びその調製方法
WO2017107895A1 (zh) 口服制剂及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20171121

Address after: Quebec

Applicant after: Softto Kimmel pharmaceutical company

Address before: Quebec

Applicant before: SUPRATEK PHARMA INC.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant